SMSamantha Maragh

Samantha Maragh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samantha Maragh has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Protocol for CRISPR-Cas9 genome editing of a swine cell line via electroporation

    by Patricia Kiesler, Stella S. Lee, Alexis L. Norris, Mayumi F. Miller, Carlo J. Mercado, Adam L. Moyer, Samantha Maragh

  • Measurement solutions and standards for advanced therapy

    by Lili Wang, Samantha Maragh, Edward Kwee, Jamie L. Almeida, Sierra D. Miller, Tara Eskandari, Sheng Lin-Gibson

  • Cybersecurity of genomic data

    by Ronald Pulivarti, Natalia Martin, Frederick R Byers, Justin Wagner, Justin Zook, Samantha Maragh, Jennifer McDaniel, Kevin Wilson, Martin Wojtyniak, Brett Kreider, et al.

    Genomic data has enabled the rapid growth of the U.S. bioeconomy and is valuable to the individual, industry, and government because it has multiple intrinsic properties that in combination make it different from other types of high value data which possess only a subset of these properties. The characteristics of genomic data compared to other high value datasets raises some correspondingly unique cybersecurity and privacy concerns that are inadequately addressed with current policies, guidance documents, and technical controls. This report describes current practices in risk management, cybersecurity, and privacy management for protecting genomic data along with relevant challenges and concerns. Gaps in protection practices across the lifecycle were identified concerning genomic data generation; safe and responsible sharing of the genomic data; monitoring the systems processing genomic data; lack of specific guidance documents addressing the unique needs of genomic data processors; and regulatory/policy gaps with respect to national security and privacy threats in the collection, storage, sharing, and aggregation of human genomic data. The report proposes a set of solution ideas that address real-life use cases occurring at various stages of the genomic data lifecycle along with candidate mitigation strategies and the expected benefits of the solutions. Additionally, areas needing regulatory/policy enactment or further research are highlighted.


  • Cybersecurity of Genomic Data

    by Ronald Pulivarti, Natalia Martin, Fred Byers, Justin Wagner, Justin Zook, Samantha Maragh, Kevin Wilson, Martin Wojtyniak, Brett Kreider, Ann-Marie France, et al.

    Genomic data has enabled the rapid growth of the U.S. bioeconomy and is valuable to the individual, industry, and government because it has multiple intrinsic properties that in combination make it different from other types of high value data which possess only a subset of these properties. The characteristics of genomic data compared to other high value datasets raises some correspondingly unique cybersecurity and privacy challenges that are inadequately addressed with current policies, guidance documents, and technical controls. This report describes current practices in risk management, cybersecurity, and privacy management for protecting genomic data along with relevant challenges and concerns. Gaps in protection practices across the lifecycle were identified concerning genomic data generation, safe and responsible sharing of the genomic data, monitoring the systems processing genomic data, lack of specific guidance documents addressing the unique needs of genomic data processors, and regulatory/policy gaps with respect to national security and privacy threats in the collection, storage, sharing, and aggregation of human genomic data. The report proposes a set of solution ideas that address real-life use cases occurring at various stages of the genomic data lifecycle along with candidate mitigation strategies and the expected benefits of the solutions. Additionally, areas needing regulatory/policy enactment or further research are highlighted.


  • Open Access

    Variability in genome-engineering source materials: consider your starting point

    by Simona Patange, Sierra D. Miller, Samantha D. Maragh

    The presence and impact of variability in cells as the source material for genome engineering are important to consider for the design, execution and interpretation of outcomes of a genome-engineering process. Variability may be present at the genotype and phenotype level, yet the impact of these sources of variability on a genome-engineering experiment may not be regularly considered by researchers. In this perspective, we use clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) genome editing of mammalian cells to provide examples of how variation within or across cell samples may mislead a researcher in their expectations about the cells they are engineering. Furthermore, we highlight the need for understanding the baseline cell genotype and phenotype to appropriately understand the starting cell material and interpret and attribute the impact of engineering on cells. We emphasize that heterogeneity within a cell pool and the inherent variability in the cellular materials used for genome engineering are complex, but of high value to characterize and account for where possible, to move toward the potential of generating desired and predictable engineered products. Provided is a framework cause-and-effect diagram for CRISPR/Cas9 genome editing toward identifying and mitigating potential sources of variability. We encourage researchers to consider the variability of source materials and undertake strategies, which may include those described here, for detecting, attributing and minimizing additional sources of variability where possible toward the aim of fostering greater reliability, confidence and reproducibility in genome-engineering studies.Graphical Abstract


  • Open Access

    Fire Burn and Cauldron Bubble: What Is in Your Genome Editing Brew?

    by Simona Patange, Samantha Maragh

    Genome editing is a rapidly evolving biotechnology with the potential to transform many sectors of industry such as agriculture, biomanufacturing, and medicine. This technology is enabled by an ever-growing portfolio of biomolecular reagents that span the central dogma, from DNA to RNA to protein. In this paper, we draw from our unique perspective as the National Metrology Institute of the United States to bring attention to the importance of understanding and reporting genome editing formulations accurately and promoting concepts to verify successful delivery into cells. Achieving the correct understanding may be hindered by the way units, quantities, and stoichiometries are reported in the field. We highlight the variability in how editing formulations are reported in the literature and examine how a reference molecule could be used to verify the delivery of a reagent into cells. We provide recommendations on how more accurate reporting of editing formulations and more careful verification of the steps in an editing experiment can help set baseline expectations of reagent performance, toward the aim of enabling genome editing studies to be more reproducible. We conclude with a future outlook on technologies that can further our control and enable our understanding of genome editing outcomes at the single-cell level.


  • Open Access

    Evaluation Protocol for CRISPR/Cas9-mediated CD19 Knockout GM24385 Cells by Flow Cytometry and Sanger Sequencing

    by Sarah L Inwood, Linhua Tian, Kirsten Parratt, Samantha Maragh, Lili Wang

    Although several genome editing options are available, CRISPR/Cas9 is one of the most commonly used systems for protein and advanced therapies. There are some long-term data regarding genomic and p... Method summary The objective of this work is to describe a protocol for using flow cytometry to measure the edits from CRISPR/Cas9 on a well-characterized B-lymphoblast cell line, GM24385, with the...


  • Evaluation of two mitochondrial DNA biomarkers for prostate cancer detection

    by Samantha Maragh, Robert W. Veltri, Steven P. Lund, Leslie Mangold, Sumit Isharwal, Christhunesa S. Christudass, Alan W. Partin, Elizabeth B. Humphreys, Lynn Sorbara, Sudhir Srivastava, et al.

    BACKGROUND: A 3.4kb deletion (3.4kbΔ ) in mitochondrial DNA (mtDNA) found in histologically normal prostate biopsy specimens has been reported to be a biomarker for the increased probability of prostate cancer. Increased mtDNA copy number is also re


  • Open Access

    Performance of mitochondrial DNA mutations detecting early stage cancer

    by John P Jakupciak, Samantha Maragh, Maura E Markowitz, Alissa K Greenberg, Mohammad O Hoque, Anirban Maitra, Peter E Barker, Paul D Wagner, William N Rom, Sudhir Srivastava, et al.

    Background: Mutations in the mitochondrial genome (mtgenome) have been associated with cancer and many other disorders. These mutations can be point mutations or deletions, or admixtures (heteroplasmy). The detection of mtDNA mutations in body fluids using resequencing microarrays, which are more sensitive than other sequencing methods, could provide a strategy to measure mutation loads in remote anatomical sites. Methods: We determined the mtDNA mutation load in the entire mitochondrial genome of 26 individuals with different early stage cancers (lung, bladder, kidney) and 12 heavy smokers without cancer. MtDNA was sequenced from three matched specimens (blood, tumor and body fluid) from each cancer patient and two matched specimens (blood and sputum) from smokers without cancer. The inherited wildtype sequence in the blood was compared to the sequences present in the tumor and body fluid, detected using the Affymetrix Genechip® Human Mitochondrial Resequencing Array 1.0 and supplemented by capillary sequencing for noncoding region. Results: Using this high-throughput method, 75% of the tumors were found to contain mtDNA mutations, higher than in our previous studies, and 36% of the body fluids from these cancer patients contained mtDNA mutations. Most of the mutations detected were heteroplasmic. A statistically significantly higher heteroplasmy rate occurred in tumor specimens when compared to both body fluid of cancer patients and sputum of controls, and in patient blood compared to blood of controls. Only 2 of the 12 sputum specimens from heavy smokers without cancer (17%) contained mtDNA mutations. Although patient mutations were spread throughout the mtDNA genome in the lung, bladder and kidney series, a statistically significant elevation of tRNA and ND complex mutations was detected in tumors. Conclusion: Our findings indicate comprehensive mtDNA resequencing can be a high-throughput tool for detecting mutations in clinical samples with potential applications for cancer detection, but it is unclear the biological relevance of these detected mitochondrial mutations. Whether the detection of tumor-specific mtDNA mutations in body fluidsy this method will be useful for diagnosis and monitoring applications requires further investigation.


  • Open Access

    Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0

    by John P Jakupciak, Andrea Maggrah, Samantha Maragh, Jennifer Maki, Brian Reguly, Katrina Maki, Roy Wittock, Kerry Robinson, Paul D Wagner, Robert E Thayer, et al.

    Background: Mutations in the mitochondrial genome (mtgenome) have been associated with many disorders, including breast cancer. Nipple aspirate fluid (NAF) from symptomatic women could potentially serve as a minimally invasive sample for breast cancer screening by detecting somatic mutations in this biofluid. This study is aimed at 1) demonstrating the feasibility of NAF recovery from symptomatic women, 2) examining the feasibility of sequencing the entire mitochondrial genome from NAF samples, 3) cross validation of the Human mitochondrial resequencing array 2.0 (MCv2), and 4) assessing the somatic mtDNA mutation rate in benign breast diseases as a potential tool for monitoring early somatic mutations associated with breast cancer. Methods: NAF and blood were obtained from women with symptomatic benign breast conditions, and we successfully assessed the mutation load in the entire mitochondrial genome of 19 of these women. DNA extracts from NAF were sequenced using the mitochondrial resequencing array MCv2 and by capillary electrophoresis (CE) methods as a quality comparison. Sequencing was performed independently at two institutions and the results compared. The germline mtDNA sequence determined using DNA isolated from the patient's blood (control) was compared to the mutations present in cellular mtDNA recovered from patient's NAF. Results: From the cohort of 28 women recruited for this study, NAF was successfully recovered from 23 participants (82%). Twenty two (96%) of the women produced fluids from both breasts. Twenty NAF samples and corresponding blood were chosen for this study. Except for one NAF sample, the whole mtgenome was successfully amplified using a single primer pair, or three pairs of overlapping primers. Comparison of MCv2 data from the two institutions demonstrates 99.200% concordance. Moreover, MCv2 data was 99.999% identical to CE sequencing, indicating that MCv2 is a reliable method to rapidly sequence the entire mtgenome. Four NAF samples contained somatic mutations. Conclusion: We have demonstrated that NAF is a suitable material for mtDNA sequence analysis using the rapid and reliable MCv2. Somatic mtDNA mutations present in NAF of women with benign breast diseases could potentially be used as risk factors for progression to breast cancer, but this will require a much larger study with clinical follow up.